R906289 Monosodium (R289 Na)
C-906289-002
Phase 2 small_molecule active
Quick answer
R906289 Monosodium (R289 Na) for Low Risk Myelodysplastic Syndromes is a Phase 2 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RIGEL PHARMACEUTICALS INC
- Indication
- Low Risk Myelodysplastic Syndromes
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active